No Data
No Data
Express News | KalVista Pharmaceuticals Presented US Subgroup Analysis From Sebetralstat Phase 3 KONFIDENT Trial, Real-world Claims And Patient Survey Data At Eastern Allergy Conference 2024, And Japanese Subgroup At Annual Meeting Of Japanese Dermatological Association
KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024
– US subgroup in the phase 3 KONFIDENT trial demonstrates median time to treatment of 38 minutes and time to beginning of symptom relief 1.3 hours – – Despite growing use of long-term prophylaxis the
Sector Update: Health Care
Health care stocks rose late Friday afternoon with the NYSE Health Care Index advancing 0.9% and the Health Care Select Sector SPDR Fund (XLV) up 0.8%. The iShares Biotechnology ETF (IBB) eased 0.1%.
KalVista Prospective Treatment for Swelling Disorder Meets Objectives -- Shares Rise
KalVista Pharmaceuticals (KALV) was advancing 4% Friday after the drugmaker said a late-stage trial of its candidate, sebetralstat, to treat hereditary angioedema, a swelling disorder, met primary and
Express News | KalVista Pharmaceuticals Presents Late-Breaking Phase 3 KONFIDENT Trial Data On Sebetralstat At EAACI Congress; NEJM Publication Highlights 9-Minute Median Time To Treatment And 1.3-Hour Symptom Relief For Laryngeal Attacks In KONFIDENT-S Trial
Express News | Kalvista Pharmaceuticals : Look Forward to Submitting New Drug Application for Sebetralstat to FDA in June 2024 & in EU and Japan Later This Year
No Data